A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

To join this study, you would need to have certain types of cancer: bowel cancer that has spread or can't be operated on, advanced pancreatic cancer, or advanced bile duct cancer. For most people, you would have already had some treatment for your cancer in the past and recovered from any side effects.

There are also some reasons why you might not be able to join. For example, if you've had severe eye problems in the past, or if you've recently had other cancer treatments, especially within the last four weeks. You also wouldn't be able to join if you have a history of serious lung conditions like pneumonitis/interstitial lung disease that needed steroid treatment, or if you currently have such conditions.

This study is open to both men and women, aged 18 and over. The research team will carefully review your medical history to make sure the study is right for you, and that it's safe for you to take part.

Taking part in this study would involve regular visits to the hospital or clinic for assessments. These assessments would help the doctors monitor your health, how you're reacting to the treatment, and how the cancer is responding. You would receive the study medication, sacituzumab tirumotecan, potentially alongside other established cancer treatments like 5-FU/Leucovorin or Cisplatin, depending on the specific group you're in. You may also receive 'rescue medication' and ‘supportive care’ to help manage any side effects. The total duration of your participation would involve the treatment period and follow-up appointments to track your progress and long-term health. The exact number of visits and the overall time commitment would be explained in full by the study team.